Key result
MEA demonstrates ~94% stability for the HPR phenotype compared to LTA.
Why the study?
The stability of the high on-treatment platelet reactivity (HPR) phenotype over time in clopidogrel-treated patients has never been investigated but is crucial for justifying intensified antiplatelet treatment beyond clinical trials.
Is the high on-treatment platelet reactivity phenotype stable over time in patients on chronic clopidogrel therapy?
Population
31 patients under chronic clopidogrel treatment (75 mg/day)
Comparison
Stability of HPR phenotype assessed by MEA vs LTA
Design
Observational study with serial platelet function assessments
Authors
Loading...
HPR stability on clopidogrel varies by assay; leaves open optimal test selection for monitoring or trials.
Observational (n=31)
Is the high on-treatment platelet reactivity phenotype stable over time in patients on chronic clopidogrel therapy?
Absolute Event Rate: 93.5% vs 68%
p-value: p=0.01
The high on-treatment platelet reactivity phenotype is stable over time in the majority of clopidogrel-treated patients, though stability varies significantly depending on the platelet function assay used.
Jaitner et al. (2010) conducted an observational in High on-treatment platelet reactivity (n=31). Multiple electrode aggregometry (MEA) vs. Light transmission aggregometry (LTA) was evaluated on Stability of the HPR phenotype over time (p=0.01). The high on-treatment platelet reactivity phenotype was stable in 93.5% of patients assessed by multiple electrode aggregometry compared to 68% by light transmission aggregometry (P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: